ClinicalTrials.gov
public full text
Public Domain
Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients
The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Management of Anticoagulant Therapy in Non-cardiac Surgery.#883049
- Outcome Terapi Covid-19 pada Pasien yang Mendapatkan Antikoagulan Profilaksis di RSPAL Dr. Ramelan Surabaya: Outcome Covid-19 Anticoagulant Prophylaxis in Covid-19 Patients at Dr. Ramelan Naval Center Hospital Surabaya#1003934
- Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants#1057540
- Evaluating of CREATIF an Anti-coagulation Clinic#832905
- Using the CHOPS score to evaluate the severe cerebral venous sinus thrombosis progression risk after anticoagulation.#678635
Record · ID 1009574
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive